Luxna Biotech Co., Ltd.

Luxna Biotech is an Osaka University spin-out biotechnology company focused on the discovery and development of antisense oligonucleotide (ASO) therapeutics. We have built LuxiAP™, a proprietary ASO drug discovery platform based on four modified nucleic acid chemistries—AmNA™, scpBNA™, GuNA™, and 5’-CP™—combined with in-house capabilities in sequence design, high-throughput synthesis, cell-based evaluation, animal studies, and pharmacokinetic assessment.

LuxiAP™ is designed to address key challenges in ASO development, particularly therapeutic window, immune activation, potency, durability, and manufacturing cost. Our nonclinical studies have demonstrated that our proprietary chemistries can reduce immune activation, improve activity and safety, and prolong ASO efficacy in target tissues including the CNS. These technologies are supported by a strong intellectual property position covering our modified nucleic acid chemistries and their applications.

Our business model combines collaborative ASO drug discovery, licensing of proprietary nucleic acid technologies, research-use oligonucleotide supply, and development of our own pipeline. Luxna has established collaborations with pharmaceutical, chemical, and academic partners across neurological diseases, metabolic disorders, oncology-related applications, and novel functional oligonucleotides. We can work flexibly with partners from feasibility studies and target-based ASO discovery through lead optimization, nonclinical development, technology licensing, and co-development.

Our internal pipeline focuses on disease areas where ASO technology can provide clear differentiation, particularly ophthalmology, neuromuscular diseases, and CNS disorders. We are currently seeking pharmaceutical partners for two of our lead programs.

In glaucoma, Luxna is developing ASO therapeutics for optic nerve protection, with the aim of addressing disease progression beyond IOP lowering. We are seeking a strategic partner for co-development and advancement toward clinical development.

In Duchenne muscular dystrophy (DMD), we are developing an anti-miR therapeutic designed to treat patients regardless of the underlying genetic mutation. The program is being advanced with academic collaborators and public research support, and we are seeking a pharmaceutical partner for further nonclinical and clinical development.

In addition, Luxna is advancing programs in spinal cord injury, ALS/repeat-expansion diseases, and multiple system atrophy. For internal programs achieving animal proof of concept, our strategy is to pursue early partnering and out-licensing and advance selected assets toward IND submission together with pharmaceutical partners.

We are actively seeking strategic partnerships with companies interested in differentiated ASO therapeutics, proprietary nucleic acid chemistry, collaborative drug discovery, and joint development of our internal pipeline.